Product Information
PROLIA 60 MG/ML SYRINGE is a brand product labeled by Amgen Inc., priced at $1862.7440 per ML under NDC 55513071021. Its NADAC has been published 101 times since Oct 30, 2024.
Strength
60 mg/mL
Manufacturer
Amgen Inc.NDC
55513071021
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
DENOSUMABApproval Type
Biologic (BLA)
FDA Application
BLA125320On Market Since
6/5/2010
Pharmacological Classes
Price Statistics
The NADAC for PROLIA 60 MG/ML SYRINGE has been published 101 times since Oct 30, 2024, and over the history we have for it it has risen 8.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1862.7440 per ML |
|---|---|
| All-time high | $1865.2728 (Jun 10, 2026) |
| All-time low | $1723.6904 (Nov 20, 2024) |
| 52-week high | $1865.2728 |
| 52-week low | $1809.1947 |
| Median price | $1809.8749 |
| Average price | $1820.8279 |
| Largest weekly change | +5.0% (Jan 15, 2025) |
| Weeks tracked | 101 |
| Tracking since | Oct 30, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 17% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
denosumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
RANK Ligand Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PROLIA 60 MG/ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for PROLIA 60 MG/ML SYRINGE, manufactured by Amgen Inc., is $1862.7440 per ML (NDC 55513071021), effective Sep 30, 2026.
How has the price of PROLIA 60 MG/ML SYRINGE changed over time?
Over the history we have for it, the NADAC for PROLIA 60 MG/ML SYRINGE has risen 8.0%. It has been tracked across 101 weekly CMS publications since Oct 30, 2024.
What are the highest and lowest recorded NADAC prices for PROLIA 60 MG/ML SYRINGE?
Since Oct 30, 2024, the NADAC for PROLIA 60 MG/ML SYRINGE has ranged from a low of $1723.6904 (Nov 20, 2024) to a high of $1865.2728 (Jun 10, 2026), with a median of $1809.8749 per ML.
Are there cheaper alternatives to PROLIA 60 MG/ML SYRINGE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, JUBBONTI 60 MG/ML SYRINGE, is $1536.9051 per ML — about 17% below PROLIA 60 MG/ML SYRINGE.
Who manufactures PROLIA 60 MG/ML SYRINGE?
PROLIA 60 MG/ML SYRINGE (NDC 55513071021) is labeled by Amgen Inc., and CMS classifies it as a brand product.